To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.
Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed OR being removed at time of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX/FOLFIRI +/- bevacizumab or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023
Must receive ≥ 4 cycles of preoperative chemotherapy
Patients with primary colorectal tumor that will remain in situ
Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori
Unwilling/unable to undergo blood draws for ctDNA, patient or provider-determined
Other active malignancies requiring treatment